What did the 71-month follow-up of the POSITIVE trial find?

No increase in long-term breast cancer recurrence risk was observed by interrupting endocrine therapy to attempt pregnancy.

Who is this study important for?

It is important for young patients with hormone receptor-positive breast cancer who wish to become pregnant and their healthcare providers.

What role did JBCRG play in this study?

JBCRG was responsible for the planning and management of the POSITIVE trial in Japan, contributing to data collection from Japanese patients.

AI News NQ Analysis

JBCRG Announces Publication of 71-Month Follow-Up Results of POSITIVE Trial in Annals of Oncology

NQ Score 0/100

N1 Content Completeness 9

Key facts

JBCRG Announces Publication of 71-Month Follow-Up Results of POSITIVE Trial in Annals of Oncology
The Japan Breast Cancer Research Group (JBCRG) announced the publication of 71-month follow-up results from the international POSITIVE trial in Annals of Oncology. The study demonstrates long-term safety of interrupting endocrine therapy for pregnancy in young women with hormone receptor-positive breast cancer.
Source: PR TIMES
Date: Mon Jun 08 2026 12:00:01 GMT+0900 (Japan Standard Time)

Direct answer

The Japan Breast Cancer Research Group (JBCRG) announced the publication of 71-month follow-up results from the international POSITIVE trial in Annals of Oncology. The study demonstrates long-term safety of interrupting endocrine therapy for pregnancy in young women with hormone receptor-positive breast cancer.

Citation: JBCRG Announces Publication of 71-Month Follow-Up Results of POSITIVE Trial in Annals of Oncology (Mon Jun 08 2026 12:00:01 GMT+0900 (Japan Standard Time)), PR TIMES
Source: PR TIMES
Date: Mon Jun 08 2026 12:00:01 GMT+0900 (Japan Standard Time)

AI Summary (NQ-processed)

The Japan Breast Cancer Research Group (JBCRG) announced the publication of 71-month follow-up results from the international POSITIVE trial in Annals of Oncology. The study demonstrates long-term safety of interrupting endocrine therapy for pregnancy in young women with hormone receptor-positive breast cancer.

AI Analysis

Frequently Asked Questions

Q: What did the 71-month follow-up of the POSITIVE trial find?: A: No increase in long-term breast cancer recurrence risk was observed by interrupting endocrine therapy to attempt pregnancy.
Q: Who is this study important for?: A: It is important for young patients with hormone receptor-positive breast cancer who wish to become pregnant and their healthcare providers.
Q: What role did JBCRG play in this study?: A: JBCRG was responsible for the planning and management of the POSITIVE trial in Japan, contributing to data collection from Japanese patients.